International Society on Thrombosis and Haemostasis, Inc.

About the 2015 ISTH Congress

Learn about the 2015 Local Organizing Committee, the ISTH Congresses and the SSC Meetings below:

Local Organizing Committee

Sam Schulman graduated from Karolinska Institute, Stockholm, Sweden in 1977 and became a specialist in Internal Medicine in 1984, with subspecialties in Haematology and in Coagulation in 1985. That year he also received his Dr Med Sc with the thesis: "Studies on the Medical Treatment of Deep Vein Thrombosis." He has worked within the field of coagulation disorders continuously since 1984, worked as a consultant at the national Hemophilia Center at Tel Hashomer, Israel from 1992-1996, and was director of the Hemophilia Treatment Center in Stockholm from 1996-2004.

His major research activities have been clinical studies in venous thromboembolism, including several randomized trials, and in hemophilia and its complications. He is currently involved in trials with new antithrombotic agents, such as the oral thrombin inhibitors. He has been a member of the Executive Committee of the World Federation of Hemophilia (2000-2004) and was chairman of the Subcommittee on Control of Anticoagulation of the SSC Subcommittee of ISTH from 2005-2008.

Dr. Schulman is associate professor in Internal Medicine at Karolinska Institute and since September 2004 also a professor in Medicine at McMaster University. He is Director of the Thrombosis Service at HHS-General Hospital in Hamilton and Director of the Clinical Thromboembolism Program of McMaster University.

Dr. Philip S. Wells, MD, FRCP(C), earned his MC and FRCP(C) in internal medicine at the University of Ottawa. Following this, he went to McMaster University to earn his FRCP(C) in Hematology and his MSc in Clinical Epidemiology.

Dr. Wells is Professor and Chair / Chair of the Department of Medicine at the University of Ottawa and The Ottawa Hospital. He is a senior scientist in the Ottawa Hospital Research Institute. He has a clinical practice in venous thromboembolic diseases and performs both laboratory and clinical trials research in the area of venous thromboembolism.

Dr. Wells’ particular interests have been in the area of improving diagnosis in patients with suspected DVT or pulmonary embolism and novel ways of treating patients. Economic issues associated with diagnostic and treatment issues have also been an interest as well as meta-analytic techniques for determining efficiencies of treatments that have not been subjected to large-scale clinical trials.

Dr. Victor Blanchette is a staff physician in the Division of Haematology/Oncology at the Hospital for Sick Children and Professor of Paediatrics at the University of Toronto. He is a Senior Associate Scientist in the Research Institute and a Clinician Investigator in the Department of Paediatrics. Dr. Blanchette received his medical training at the University of Cambridge and St. Bartholomew's Hospital in the UK. His post-graduate medical training included a paediatric residency at Johns Hopkins Hospital and a fellowship in paediatric haematology/oncology at McMaster University Medical Centre in Canada.

Dr. Blanchette's research interest is in the area of the congenital and acquired bleeding disorders of children. He is Director of the Paediatric Haemophilia and Thrombosis/Bleeding Disorders Programs at the Hospital for Sick Children and is Chairman of the Factor Prophylaxis Subcommittee of the Association of the Hemophilia Clinic Directors of Canada (AHCDC). Dr. Blanchette is Chair of the Canadian Paediatric Thrombosis and Hemostasis Network and a founding member of an Intercontinental ITP Study Group.

In 2002, Dr. Blanchette was appointed as the Inaugural Holder of the Women’s Auxillary Millenium Chair in Paediatric Haematology/Oncology. Dr. Blanchette is Principal Investigator for the Hospital for Sick Children in the Children's Oncology Group (COG) and he is Co-Chair of the recently formed Council of Canadian Paediatric Haematology/Oncology Directors Group. Dr. Blanchette is an elected fellow of the Royal College of Physicians and Surgeons of the UK.

Dr. Jeffrey Weitz, MD, is a Professor of Medicine and Biochemistry at McMaster University and Director of the Juravinski Hospital and Cancer Centre. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz now focuses his clinical work in the area of thrombosis. He is the recipient of a Career Investigator Award from the Heart and Stroke Foundation of Canada and holds an Endowed Chair in Cardiovascular Research at McMaster University.

Dr. Weitz brings a 30 year career that spans the spectrum from basic research in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and atherosclerosis and on to clinical trials and health outcomes research. He has held multiple leadership roles in scientific administration, education, and publishing, and also has a strong background in evidence-based medicine. He is a clinician trained in hematology, medical oncology and vascular medicine and works to integrate basic science with clinical practice to rapidly translate new discoveries to the bedside.

Dr. David Lillicrap, MD, is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, Kingston, Canada. Since 2000, he has been the recipient of a Canada Research Chair in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. He has served on the Gene Therapy Working Group of the US National Hemophilia Foundation (NHF) and has been a member of NHF’s Medical and Scientific Advisory Committee. He is the Chair of the Research Committee of the World Federation of Hemophilia (WFH) and is a member of the Medical Advisory Board of the WFH. He recently completed a three-year term as the chairperson of the ISTH's SSC Subcommittee on von Willebrand Factor, and is the current Chair of the Society’s SSC. He is an Associate Editor of the journal Blood, and a member of the editorial board of the British Journal of Haematology.

His research program relates to molecular aspects of the hemostatic system with particular emphasis on novel therapeutic approaches and immunological complications of hemophilia A, and the genetics, biology and pathobiology of von Willebrand Factor.



Dr. Margaret Rand is a Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology, with cross-appointments to Biochemistry and to Paediatrics, and a Senior Associate Scientist in the Research Institute and the Division of Haematology/Oncology at The Hospital for Sick Children. She obtained her PhD in Biochemistry at the University of Toronto with Dr. Marian Packham, and did post-doctoral training at the Rijksuniversiteit Limburg (now Maastricht University) in The Netherlands and at McMaster University in Hamilton.

Her research program, funded by the Heart and Stroke Foundation of Ontario/Canada, has focused on investigations of biochemical mechanisms involved in platelet function and dysfunction. A more recent clinical research interest at SickKids has been in the development and validation of standardized pediatric bleeding questionnaires. Dr. Rand is Co-Chair of the Rare Inherited Bleeding Disorders Subcommittee of the Association of Hemophilia Clinic Directors of Canada, and a member of the Hemostasis Committee of the Canadian Pediatric Thrombosis and Hemostasis Network.

Dr. Peter Gross is an Associate Professor at McMaster University in the Department of Medicine in the Division of Hematology and Thromboembolism. He received his B.Sc at the University of Toronto, then his M.Sc. in the Department of Biochemistry under the supervision of Dr. Margaret Rand. He obtained his M.D. from the University of Toronto in 1994, then did Core Internal Medicine training at the same institution. Dr. Gross then did clinical training in Hematology and Oncology at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, in Boston, MA. Dr. Gross then spent four years as a postdoctoral fellow in the laboratory of Drs. Bruce and Barbara C. Furie at the Center for Hemostasis and Thrombosis Research at Harvard Medical School.

Prior to coming to McMaster University, Dr. Gross was an Assistant Professor and Clinician Scientist in the Department of Medicine at St. Michael’s Hospital and the University of Toronto. Through his training Dr. Gross received personal support awards from the Heart and Stroke Foundation of Ontario and the Canadian Institutes of Health Research. He was also a recipient of the Bayer Worldwide Hemophilia Awards Program, Early Career Award, 2005-2007.

Dr. Gross’s overall research interest is the pathophysiology of vascular disorders, specifically thrombosis, with a goal to develop novel strategies to treat patients with these disorders. The approach is to use experimental models of these disorders to evaluate the roles of defined cells or molecules.

Dr. Paula James is an Associate Professor in the Department of Medicine, with cross-appointments to Pathology & Molecular Medicine and Pediatrics. She joined the Faculty in July of 2004 and is a Clinician Scientist with 75% protected time for research. Dr. James is a Principal Investigator in the Clinical and Molecular Hemostasis Research Group at Queen’s University with an active research program investigating the genetic basis of inherited bleeding disorders as well as the quantitation of bleeding symptoms. Her group is comprised of post-doctoral fellows, graduate students and well as research associates.

In recent years, activities have included validating and publishing the Condensed MCMDM-1VWD Bleeding Questionnaire, which has gained international recognition as well as optimizing a protocol for culturing BOEC (Blood Outgrowth Endothelial Cells) from patients with both inherited and acquired diseases.

In addition to her research activities, Dr. James is the Medical Director of the Southeastern Ontario Inherited Bleeding Disorders Program and its aligned Women and Bleeding Disorders Clinic. She was awarded "Researcher of the Year” by the National Hemophilia Foundation (US organization) in 2011, and the Mihran and Mary Basmajian Award for Excellence in Health Research by the Faculty of Health Sciences at Queen’s University in 2012.

Ed Conway, MD, PhD, MBA was born and educated in Toronto, receiving degrees in Electrical Engineering and Medicine at the University of Toronto. He completed training in Hematology and Oncology in Boston at Harvard University and at MIT and returned to the University of Toronto as a Research Scholar with the Heart and Stroke Foundation.

In 1995, Dr. Conway was recruited to the University of Leuven and the Flanders Institute for Biotechnology (VIB) in Belgium, where he led a research group that explored the vasculoprotective properties of thrombomodulin and survivin.

Dr. Conway moved to Vancouver in 2009 as the Director of the Centre for Blood Research (CBR) at the University of British Columbia, where he is a Professor of Medicine, a Staff Hematologist at the Vancouver General Hospital, and holds a Canada Research Chair in Endothelial Cell Biology. Dr. Conway's research, supported by grants from the Canadian Institutes for Health Research and the Natural Sciences and Engineering Research Council of Canada, is currently focused on characterizing the interplay between the coagulation system and the complement system.

Jerry Teitel is a Hematologist specializing in hemophilia and related bleeding disorders. His clinical and research training was at the University of Toronto and Harvard University. He is Director of the Adult Hemophilia Treatment Centre at St. Michael's Hospital in Toronto, and is a Professor in the Department of Medicine at the University of Toronto.

He has had leadership positions in the Association of Hemophilia Clinic Directors of Canada (AHCDC), the Hemophilia and Thrombosis Research Society, and the Canadian Hematology Society. He is a member of the Inhibitor Committee and the Factor IX Committee of the AHCDC, and is Administrative Vice-President of that organization.

Dr. Marc Rodger, M.D., FRCP(C), MSc. is a Professor in the Faculty of Medicine, Departments of Medicine, Epidemiology and Community Medicine and Obstetrics and Gynecology. He is the Chief and Chair of the Division of Hematology and the Head of the Thrombosis Program. He is a Senior Scientist at the Ottawa Hospital Research Institute. He holds a Faculty of Medicine Clinical Research Chair in Venous Thrombosis and Thrombophilia and a Career Scientist Award from the Heart and Stroke Foundation of Canada. Dr. Rodger’s research program is focused on Venous Thrombosis and Thrombophilia with specific focus on 1) Thrombosis/ Thrombophilia in Pregnancy and 2) Venous Thrombosis: Optimal Management.

Dr. Rodger founded the Ottawa Hospital General Campus Thrombosis Program in 1998, led the successful merger with the Civic Campus Thrombosis Program founded by Dr. Wells in 2002 and led the development of the Champlain LHIN Regional Thrombosis Program which was launched in 2010. In 2012, as Chief of Hematology he also led the development of The Ottawa Blood Disease Center: A state of the art world class facility housing the clinical, research, teaching and administrative components of the Division of Hematology.

Geoffrey Werstuck received his BSc and his PhD in Biochemistry in 1987 and 1993, respectively at McMaster University where he is currently Associate Professor at the Division of Hematology & Thromboembolism, Department of Medicine, and Department of Biochemistry & Biomedical Sciences. His research interests are in the investigation of the mechanism(s) by which diabetes promotes the development and progression of atherosclerosis.

Geoffrey is the Principal Investigator in a number of related studies funded by Heart and Stroke Foundation of Canada, Heart and Stroke Foundation of Ontario, Hamilton Health Sciences Foundation, and Canadian Institutes of Health Research. He is the recipient of several awards including the Margaret Becklake Thematic Symposium Award, and is very involved in teaching, training, and supervising both graduate and undergraduate students.

John Eikelboom, MBBS, MSc, FRCPC is Associate Professor in the Department of Medicine, McMaster University, and haematologist in the Thrombosis Service, Hamilton General Hospital, Ontario, Canada. He originally trained in Internal Medicine and Haematology in Perth, Australia and subsequently moved to Hamilton to take up a Tier II Canada Research Chair in Cardiovascular Medicine. Dr Eikelboom has co-authored more than 350 articles in peer-reviewed journals.

His current research, supported by the Canadian Institutes for Health Research, the Heart and Stroke Foundation and the National Health and Medical Research Council of Australia, focuses on the efficacy and safety of antithrombotic therapies, outcomes after blood transfusion and bleeding, and the mechanisms of variable response to antiplatelet drugs.

John Semple is Professor of Pharmacology, Medicine, Laboratory Medicine & Pathobiology and Senior Staff Scientist at the Keenan Research Centre, Li Ka Shing Knowledge Institute, and at Toronto Platelet Immunobiology Group, St. Michael's Hospital. He is also Adjunct Scientist, at the Canadian Blood Services.

His research is aimed at understanding the cellular immune mechanisms responsible for the generation of both auto and allo IgG antibodies that recognize platelet antigens. These mechanisms can be exploited to develop immune specific therapies which suppress these clinically significant IgG immune responses. John Semple is specifically interested in how platelet antigens are processed and presented by antigen presenting macrophages to T helper lymphocytes and how these intracellular biochemical events can control platelet immunity. The pro-inflammatory nature of platelets that may be responsible for adverse reactions from platelet transfusions is also an interest of my laboratory. Specifically, how platelet TLR expression modulates innate immune mechanisms.

He is also studying the mechanisms of action that intravenous gammaglobulin and anti D preparations utilize to increase platelet counts in immune-mediated thombocytopenic disorders. These therapies have become primary treatments in these disorders and little is known of how they mediate their effects. The projects in John Semple’s laboratory offer the opportunity to learn many techniques in cellular immunology, immunochemistry, HPLC, tissue culture, flow cytometry and animal handling.

Dr. Mark Crowther is Professor, Department of Medicine, Hematology and Thromboembolism and Pathology and Molecular Medicine, McMaster University, Director of Laboratory Hematology, Hamilton Regional Laboratory Medicine Program, and Chief of Laboratory Medicine, St Joseph’s Healthcare and Hamilton Health Sciences. Vice President, Research, St. Joseph's Healthcare System and he has a Leo Pharma Chair in Thromboembolism Research at McMaster University. Dr. Crowther holds a Career Investigator Award from the Heart and Stroke Foundation of Ontario.

His current research interests include exploring ways of improving the way that we use our current anticoagulant drugs; foci include exploring the use of vitamin K to treat warfarin-associated coagulopathy, the use of low molecular weight heparin in patients with renal failure, and studies and systematic reviews of various interventions and observations in Hematology and Thromboembolism.

Dr. Donald Arnold, MDCM, MSc, FRCP(C), is Associate Professor in the Department of Medicine at McMaster University in Hamilton, Canada and co-director of the McMaster Platelet Immunology Laboratory. He is the Program Director for the McMaster Transfusion Medicine Residency Training Program and Director of Research for the Internal Medicine Residency Training Program.

Dr. Arnold obtained his Medical Degree from McGill University and completed training in Internal Medicine at the Jewish General Hospital in Montreal. He completed Hematology training at McMaster University in 2003, Fellowship in Transfusion Medicine in 2005 and a Master’s degree in Health Research Methodology from McMaster in 2007. He is the recipient of a New Investigator Award from the Canadian Institutes of Health Research.

Dr. Arnold is a translational researcher in platelet immunology. He is lead investigator for several clinical studies in immune thrombocytopenia (ITP) and is heading a basic and clinical program of research designed to examine the pathophysiology of primary ITP. Other research interests include best practices of blood transfusions with a focus on critically ill patients.

Temporary replacement for Michele David.

Patti Massicotte, an expert in Pediatric Thrombosis and Antithrombotic Therapy, is the Director of the KIDCLOT program and Professor of Pediatrics at the University of Alberta. Her research interests currently focus on antithrombotic therapy in infants, children and adolescents with congenital and acquired heart disease, and she consults with the NIH/NHLBI in this area.

Laurie Sardo is a clinical research nurse at McMaster University in Hamilton in the Department of Medicine, Clinical Thromboembolism Program. Laurie obtained her RN diploma at Fanshawe College and subsequently completed her BScN, Masters in Nursing and nurse practitioner diploma from McMaster University.

Laurie was instrumental in starting up the Thrombosis nursing journal club in Hamilton. Her interests lie with patient and staff education with new oral anticoagulants and is currently co-Investigator on a registry study looking at gastrointestinal symptoms associated with dabigatran use.

Dr. Lori Linkins is Associate Professor at the Division of Hematology and Thromboembolism, Department of Medicine, McMaster University. Her primary research interests include bleeding on anticoagulant therapy, cancer-associated thrombosis and diagnosis and treatment of heparin-induced thrombocytopenia. She has been the recipient of career and research funding awards from the Heart & Stroke Foundation and Canadian Institutes of Health Research. She is currently a staff consultant on venous thromboembolism at the Juravinski Hospital and Cancer Centre.

Dr. Shannon Bates, a haematologist with expertise in the field of thromboembolism, received her subspecialty training at McMaster University. She is Associate Professor at the Department of Medicine and Director of the Division of Hematology and Thromboembolism, McMaster University. Her clinical activities are based at the McMaster Division of Hamilton Health Sciences. Simplification of the diagnosis of venous thromboembolism, development of new diagnostic strategies in patient populations not well served by currently available techniques, and venous thromboembolism in pregnancy are among her research interests.

Dr. Bates is the principal investigator of an international multicentre trial funded by the Canadian Institutes of Health Research examining the role of D-dimer testing in patients with suspected recurrent deep vein thrombosis and the co-principal investigator of a Heart and Stroke Foundation of Ontario-funded multicentre study evaluating a new diagnostic strategy in suspected pulmonary embolism. She is the recipient of a New Investigator Award from the Canadian Institutes of Health Research University-Industry Program. Dr. Bates is also Chair, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (Eighth Edition): Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy.

Dr. Rita Selby, MBBS, FRCPC, MSc, is the Medical Director of the Coagulation Laboratories at the University Health Network and Sunnybrook Health Sciences Centre, both academic teaching hospitals fully affiliated with the University of Toronto. These coagulation laboratories provide special coagulation testing for the two hospitals, several regional Greater Toronto Area hospitals, two major commercial laboratories and also provide medical directorship to several Northern Ontario cluster hospitals through a partnership with the University Health Network.

She is also a consultant hematologist at Sunnybrook Health Sciences Centre specializing in thrombosis and hemostasis, medical director of the Sunnybrook Anticoagulant Management Clinic and an Assistant Professor at the University of Toronto.

She has a Masters in Clinical Epidemiology from the University of Toronto and her research interests include coagulation laboratory quality assurance and clinical research in thrombosis and anticoagulation.

Dr. Carol Gonsalves is a Clinician Educator in the Division of Hematology at The Ottawa Hospital, is a Thrombosis Consultant in the affiliated Thrombosis Program and an Assistant Professor in the Department of Medicine. She is a Clinical Investigator with the Ottawa Hospital Research Institute.

Dr. Gonsalves obtained her BSc and M.D. from the University of Ottawa and completed her Internal Medicine training at Dalhousie University in Halifax. She returned to Ottawa where she completed a Hematology Fellowship with additional clinical training in Thrombosis Medicine. She holds a Masters degree of Medical Education from the University of Dundee.

Dr. Gonsalves is the national lead for the application for Thrombosis Medicine to be recognized as an accredited diploma program with the Royal College of Physicians and Surgeons of Canada.


ISTH 2015 Senior Advisory Board

Morris Blajchman (Hamilton, Canada)
Cedric Carter (Vancouver, Canada)
Bernadette Garvey (Toronto, Canada)
Jeff Ginsberg (Hamilton, Canada)
Jack Hirsh (Hamilton, Canada)
John Kelton (Hamilton, Canada)
Raelene Kinlough-Rathbone (Hamilton, Canada)
Michael Mant (Edmonton, Canada)
Marian Packham (Toronto, Canada)
Graham Pineo (Calgary, Canada)
Georges Rivard (Montreal, Canada)
Graham Turpie (Dundas, Canada)


ISTH Congresses

At the ISTH Congress, thousands of the world’s leading experts on thrombosis, haemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care.

Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement.

For more, click here to visit the ISTH website.

SSC Meetings

The ISTH’s Scientific and Standardization Committee (SSC) holds annual meetings devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and throm­botic disorders.

In odd years, SSC Meetings are held jointly with the ISTH Congress.

For more, click here to visit the ISTH website.


Key Dates

March 11, 2015
Early Registration Deadline

June 15, 2015
Online Registration Deadline

June 20-25, 2015
ISTH 2015